Modality
Peptide
MOA
PLK4i
Target
KRASG12C
Pathway
Angiogenesis
DLBCLMelanoma
Development Pipeline
Preclinical
~Apr 2015
→ ~Jul 2016
Phase 1
~Oct 2016
→ ~Jan 2018
Phase 2
Apr 2018
→ Sep 2028
Phase 2Current
NCT03208918
594 pts·DLBCL
2018-04→2028-09·Terminated
594 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-152.5y awayPh2 Data· DLBCL
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2028-09-15 · 2.5y away
DLBCL
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03208918 | Phase 2 | DLBCL | Terminated | 594 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |